JP6142446B2 - 関節軟骨の保護のための組成物および方法 - Google Patents
関節軟骨の保護のための組成物および方法 Download PDFInfo
- Publication number
- JP6142446B2 JP6142446B2 JP2016516634A JP2016516634A JP6142446B2 JP 6142446 B2 JP6142446 B2 JP 6142446B2 JP 2016516634 A JP2016516634 A JP 2016516634A JP 2016516634 A JP2016516634 A JP 2016516634A JP 6142446 B2 JP6142446 B2 JP 6142446B2
- Authority
- JP
- Japan
- Prior art keywords
- articular cartilage
- protection
- calebin
- effective amount
- compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 210000001188 articular cartilage Anatomy 0.000 title claims description 26
- 238000000034 method Methods 0.000 title claims description 11
- 239000000203 mixture Substances 0.000 title description 6
- 230000006378 damage Effects 0.000 claims description 17
- UYEWRTKHKAVRDI-UHFFFAOYSA-N Calebin A Natural products C1=C(O)C(OC)=CC(C=CC(=O)COC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 UYEWRTKHKAVRDI-UHFFFAOYSA-N 0.000 claims description 16
- UYEWRTKHKAVRDI-ASVGJQBISA-N Calebin A Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)COC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 UYEWRTKHKAVRDI-ASVGJQBISA-N 0.000 claims description 16
- 230000001575 pathological effect Effects 0.000 claims description 15
- 241000124008 Mammalia Species 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 241000700159 Rattus Species 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 8
- 210000002683 foot Anatomy 0.000 description 6
- 210000005222 synovial tissue Anatomy 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 208000014674 injury Diseases 0.000 description 4
- 206010018691 Granuloma Diseases 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 230000008733 trauma Effects 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 230000002917 arthritic effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000000548 hind-foot Anatomy 0.000 description 2
- 210000001503 joint Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 208000009386 Experimental Arthritis Diseases 0.000 description 1
- 208000034693 Laceration Diseases 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 244000158441 Pleurotus sajor caju Species 0.000 description 1
- 235000004116 Pleurotus sajor caju Nutrition 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003356 anti-rheumatic effect Effects 0.000 description 1
- 210000000544 articulatio talocruralis Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000003237 epithelioid cell Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
Description
関節軟骨は、骨の関節表面を覆って滑膜関節を形成している特殊な結合組織である。関節軟骨は、滑膜関節に、低摩擦と比較的無痛の運動をもたらす能力を授与している。関節軟骨の構造および機能は、外傷(落下または事故)、擦傷および裂傷並びに基礎病的疾患症状の後に損傷する傾向を有する。関節軟骨組織は、通常、損傷または疾病後に再生(自己修復プロセス)せず、組織の喪失および欠損の形成をもたらす。そのような非再生に寄与する原因としては、(i) 少ない細胞成分、(ii) 貧弱な代謝および(iii) 生来の軟骨細胞の、濃密なマトリックス繊維故の組織内で***し移動する制限された能力がある。従って、関節軟骨を外傷および疾患による損傷から保護することのできる活性成分は、そのような外傷を受けやすい個々人の生活の質を改善する注目に値する範囲を提供する重要な技術的領域を構成する。
本発明は、上記の目的を満たし、さらに、関連する利点を提供する。
本発明は、カレビンAおよびその組成物の哺乳類関節軟骨に対する病的損傷を阻止する可能性に関する。
本発明は、以下の利点を提供する。
1.カレビンAおよびその組成物の哺乳類関節軟骨に対する病的損傷を阻止する新規な治療可能性の開示。
最も好ましい実施態様において、本発明は、哺乳類の関節軟骨を病的損傷から保護するためのカレビンAの有効量での使用方法に関し、該方法は、上記保護を必要とする哺乳類に有効量のカレビンAを投与する処置を含むことを特徴とする。
動物モデルにおけるアジュバント誘発関節炎
使用動物:
いずれか一方の性別のアルビノウィスター(Albino Wistar)ラット
動物の体重:
140〜180グラム
動物数/群:
05匹
慢性関節炎を、ラットにおいて、液体パラフィン中で均質化した不活化ヒト型結核菌(Mycobacterium tuberculosis)の(0.5%w/v)懸濁液の0.05mLを左後足に注入することによって誘発させた。
対照および処置群の動物の右足関節を後足から分離し、秤量し、10%緩衝ホルマリン中に24時間浸漬し、その後、10%EDTA中で脱灰処理した。その後、関節を脱水し、処理し、パラフィン(56C〜58C)ブロックを作成し、染色し(ヘマトキシリンおよびエオシン)、複合顕微鏡によって検査した(Patel P, Patel D, Patel N. Experimental investigation of anti-rheumatoid activity of Pleurotus sajorcaju in adjuvant-induced arthritic rats. Chinese Journal of Natural Medicines, 2012; 10 (4): 0269‐0274)。
対照関節炎群のラット足組織(図1)は、滑膜組織によって局所的に損傷した関節軟骨(矢印)を示していた。関節軟骨と滑膜組織は、散在性類上皮細胞を含む大量の好酸性の乾酪壊死(caeseous necrosis)によって置換わっており、僅かな貧弱に形成されたはっきりしない肉芽腫が存在していた。
本発明は、さらに、以下の態様であり得る。
[1]
哺乳類の関節軟骨を病的損傷から保護するためのカレビンAの有効量での使用方法であって、前記保護を必要とする哺乳類に有効量のカレビンAを投与する処置を含むことを特徴とする前記使用方法。
[2]
哺乳類の関節軟骨の病的損傷からの保護方法であって、前記保護を必要とする哺乳類に有効量のカレビンAを投与する処置を含むことを特徴とする前記保護方法。
Claims (4)
- 哺乳類の関節軟骨を病的損傷から保護するための医薬組成物であって、前記保護を必要とする哺乳類に有効量のカレビンAを含むことを特徴とする前記医薬組成物。
- 哺乳類の関節軟骨の病的損傷から保護するための医薬組成物を調製するための、前記哺乳類の関節軟骨の病的損傷からの保護を必要とする哺乳類に有効量のカレビンAの使用。
- 非ヒト哺乳類の関節軟骨を病的損傷から保護するためのカレビンAの有効量での使用方法であって、前記保護を必要とする非ヒト哺乳類に有効量のカレビンAを投与する処置を含むことを特徴とする前記使用方法。
- 非ヒト哺乳類の関節軟骨の病的損傷からの保護方法であって、前記保護を必要とする非ヒト哺乳類に有効量のカレビンAを投与する処置を含むことを特徴とする前記保護方法。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2014/010993 WO2015105501A1 (en) | 2014-01-10 | 2014-01-10 | Composition and method for the protection of articular cartilage |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016520126A JP2016520126A (ja) | 2016-07-11 |
JP6142446B2 true JP6142446B2 (ja) | 2017-06-07 |
Family
ID=53524213
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016516634A Expired - Fee Related JP6142446B2 (ja) | 2014-01-10 | 2014-01-10 | 関節軟骨の保護のための組成物および方法 |
Country Status (9)
Country | Link |
---|---|
JP (1) | JP6142446B2 (ja) |
KR (2) | KR101685263B1 (ja) |
AU (1) | AU2014201769B2 (ja) |
CA (1) | CA2935898C (ja) |
EA (1) | EA027614B1 (ja) |
NZ (1) | NZ622909A (ja) |
PH (1) | PH12016501138B1 (ja) |
SG (1) | SG11201605336YA (ja) |
WO (1) | WO2015105501A1 (ja) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6887898B1 (en) | 1999-10-22 | 2005-05-03 | Darrick S. H. L. Kim | Pharmaceutical compositions useful in prevention and treatment of beta-Amyloid protein-induced disease |
GB2439960B (en) | 2006-07-08 | 2011-11-16 | Redweb Security | Material for marking an article using DNA |
EP2040696B1 (en) * | 2006-07-14 | 2017-01-25 | DSM IP Assets B.V. | Compositions and use thereof for the treatment, co-treatment or prevention of inflammatory disorders |
US8577013B1 (en) | 2011-01-10 | 2013-11-05 | West Corporation | Automatic communications forwarding to displaced employees |
-
2014
- 2014-01-10 KR KR1020147009279A patent/KR101685263B1/ko active IP Right Grant
- 2014-01-10 CA CA2935898A patent/CA2935898C/en active Active
- 2014-01-10 SG SG11201605336YA patent/SG11201605336YA/en unknown
- 2014-01-10 NZ NZ622909A patent/NZ622909A/en not_active IP Right Cessation
- 2014-01-10 WO PCT/US2014/010993 patent/WO2015105501A1/en active Application Filing
- 2014-01-10 AU AU2014201769A patent/AU2014201769B2/en not_active Ceased
- 2014-01-10 JP JP2016516634A patent/JP6142446B2/ja not_active Expired - Fee Related
- 2014-01-10 KR KR1020167014135A patent/KR101685333B1/ko active IP Right Grant
- 2014-01-10 EA EA201591212A patent/EA027614B1/ru unknown
-
2016
- 2016-06-13 PH PH12016501138A patent/PH12016501138B1/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20150105185A (ko) | 2015-09-16 |
CA2935898C (en) | 2018-11-06 |
PH12016501138A1 (en) | 2016-07-18 |
KR20160087387A (ko) | 2016-07-21 |
AU2014201769B2 (en) | 2018-05-24 |
AU2014201769A1 (en) | 2015-07-30 |
PH12016501138B1 (en) | 2016-07-18 |
KR101685333B1 (ko) | 2016-12-09 |
NZ622909A (en) | 2018-04-27 |
JP2016520126A (ja) | 2016-07-11 |
EA201591212A1 (ru) | 2015-10-30 |
KR101685263B1 (ko) | 2016-12-09 |
WO2015105501A1 (en) | 2015-07-16 |
SG11201605336YA (en) | 2016-07-28 |
EA027614B1 (ru) | 2017-08-31 |
EA201591212A8 (ru) | 2016-05-31 |
CA2935898A1 (en) | 2015-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Lei et al. | Injectable hydrogel microspheres with self-renewable hydration layers alleviate osteoarthritis | |
Roosendaal et al. | Pathogenesis of haemophilic arthropathy | |
Martinello et al. | Effects of in vivo applications of peripheral blood‐derived mesenchymal stromal cells (PB‐MSCs) and platlet‐rich plasma (PRP) on experimentally injured deep digital flexor tendons of sheep | |
Raines et al. | Efficacy of particulate amniotic membrane and umbilical cord tissues in attenuating cartilage destruction in an osteoarthritis model | |
Xing et al. | Effects of various decellularization methods on histological and biomechanical properties of rabbit tendons | |
She et al. | Evaluation of a novel artificial tear in the prevention and treatment of dry eye in an animal model | |
Souza-Mello et al. | Pancreatic ultrastructural enhancement due to telmisartan plus sitagliptin treatment in diet-induced obese C57BL/6 mice | |
Patel et al. | Aligned nanofibers of decellularized muscle extracellular matrix for volumetric muscle loss | |
Schulze-Tanzil | Experimental therapeutics for the treatment of osteoarthritis | |
Stratos et al. | Open blunt crush injury of different severity determines nature and extent of local tissue regeneration and repair | |
Marino‑Martínez et al. | Human amniotic membrane intra‑articular injection prevents cartilage damage in an osteoarthritis model | |
Ekman et al. | Morphology of normal and osteochondrotic porcine articular-epiphyseal cartilage: a study in the domestic pig and minipig of wild hog ancestry | |
Mikheeva et al. | Fatty acid amide hydrolase inhibitor URB597 may protect against kainic acid–induced damage to hippocampal neurons: Dependence on the degree of injury | |
Yin et al. | NO-1886 decreases ectopic lipid deposition and protects pancreatic beta cells in diet-induced diabetic swine | |
JP6142446B2 (ja) | 関節軟骨の保護のための組成物および方法 | |
Karim et al. | Hyperosmolarity normalizes serum-induced changes to chondrocyte properties in a model of cartilage injury | |
Elder et al. | Effects of short‐duration treatment of cartilage with punicalagin and genipin and the implications for treatment of osteoarthritis | |
KR20170102879A (ko) | 15-hepe를 포함하는 조성물 및 이를 이용한 섬유증의 치료 또는 예방하는 방법 | |
EP2893926B1 (en) | Composition and method for the protection of articular cartilage | |
Nisbet et al. | Evaluation of bee venom and hyaluronic acid in the intra-articular treatment of osteoarthritis in an experimental rabbit model | |
Pollock et al. | In vivo effects of fluoroquinolones on rabbit corneas | |
Nosivets et al. | Histological changes following the administration of two different chondroitin sulfate products in experimental osteoarthritis models in rats | |
US20210386823A1 (en) | Therapeutic agent for cartilage disorder | |
Dashputra et al. | Effect of ketamine on seizure activity and its interactions with antiepileptic drugs in rats | |
RU2246304C1 (ru) | Способ коррекции деструктивно-дистрофических изменений в суставах животных |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160822 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20161122 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170120 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170417 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170420 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6142446 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
LAPS | Cancellation because of no payment of annual fees |